RxDoctor Payments Data

Michael Woolman

Family Medicine · Ogden, UTNPI 1508833450

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,809 of the $8,333 with a category attached, or 81.7%. Eli Lilly accounts for 73.9% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,333in general payments, 2019–2025

Across 68 payments — averaging $122.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$6K
  • AstraZeneca$2K
  • Novo Nordisk AS$400
$1,753,295in research payments, 2019–2025

Across 248 payments — averaging $7069.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1.3M
  • AbbVie$258K
  • AstraZeneca$72K
  • Dexcom, Inc.$47K
  • Urovant Sciences Inc$38K
  • Sumitomo Pharma America, Inc.$26K
  • plus $21K from 1 others

What the payments were for

  • Travel & lodging$6,80982%
  • Food & beverage$1,48718%
  • Education$360%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly52$6,160
AstraZeneca15$1,773
Novo Nordisk AS1$400

How this compares

$8,333 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah →

Other family medicine in Ogden

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →